These conclusions imply that the activation of TLR2, TLR4, TLR9 and MyD88 along with downstream inflammatory signaling pathways are crucial in the development and progression of NAFLD to NASH (Figure 3). The gene discussed is TLR9; the disease is metabolic dysfunction-associated steatohepatitis.